TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Interest Expense : $-6.80 Mil (TTM As of Sep. 2016)

View and export this data going back to 2013. Start your Free Trial

What is TetraLogic Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. TetraLogic Pharmaceuticals's interest expense for the three months ended in Sep. 2016 was $ -1.76 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2016 was $-6.80 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. TetraLogic Pharmaceuticals's Operating Income for the three months ended in Sep. 2016 was $ -3.76 Mil. TetraLogic Pharmaceuticals's Interest Expense for the three months ended in Sep. 2016 was $ -1.76 Mil. TetraLogic Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

TetraLogic Pharmaceuticals Interest Expense Historical Data

The historical data trend for TetraLogic Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TetraLogic Pharmaceuticals Interest Expense Chart

TetraLogic Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Interest Expense

-0.01

-0.07

-2.77

-3.36

-6.38

TetraLogic Pharmaceuticals Quarterly Data
	Dec11	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Interest Expense	Get a 7-Day Free Trial														-1.61	-1.64	-1.68	-1.72	-1.76

TetraLogic Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.80 Mil.

TetraLogic Pharmaceuticals (OTCPK:TLOG) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

TetraLogic Pharmaceuticals's Interest Expense for the three months ended in Sep. 2016 was $-1.76 Mil. Its Operating Income for the three months ended in Sep. 2016 was $-3.76 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2016 was $30.81 Mil.

TetraLogic Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2016 is calculated as

TetraLogic Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TetraLogic Pharmaceuticals Corp (OTCPK:TLOG) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

343 Phoenixville Pike, Malvern, PA, USA, 19355

Website

http://www.tetralogicpharma.com

TetraLogic Pharmaceuticals Corp is a biopharmaceutical company. The company is engaged in developing novel small molecule therapeutics in oncology.

Executives

Hudson Bay Capital Management Lp	other: See Remarks	28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Lazard Asset Management Llc	other: See Remarks	30 ROCKEFELLER PLZ, 56TH FL., NEW YORK NY 10112
Nomura Holdings Inc	other: See Remarks	1-13-1 NIHONBASHI, CHUO-KU, TOKYO M0 103-8645
Whitebox Multi-strategy Partners Lp	other: See Remarks	3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Pandora Select Partners, L.p.	other: See Remarks	3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Whitebox General Partner Llc	other: See Remarks	3033 EXCELSIOR BLVD., SUITE 300, MINNEAPOLIS MN 55416
Highbridge Capital Management Llc	other: See Remarks	277 PARK AVE, 23RD FLOOR, NEW YORK NY 10172
Sander Gerber	other: See Remarks	C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Whitebox Concentrated Convertible Arbitrage Partners, L.p.	other: See Remarks	3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Whitebox Advisors Llc	other: See Remarks	3033 EXCELSIOR BLVD., SUITE 500, MINNEAPOLIS MN 55416
Patrick Hutchison	officer: CFO & Treasurer	C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
Clarus Ventures Ii, Llc	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Lifesciences Ii, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Ventures Ii Gp, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Nicholas Simon	10 percent owner	101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142

TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Headlines

No Headlines